280 related articles for article (PubMed ID: 32231761)
1. Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Zhang ZY; Wang ZM; Huang Y
World J Hepatol; 2020 Mar; 12(3):72-83. PubMed ID: 32231761
[TBL] [Abstract][Full Text] [Related]
2. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.
Abu-Wasel B; Walsh C; Keough V; Molinari M
World J Gastroenterol; 2013 Sep; 19(35):5775-86. PubMed ID: 24124322
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of polycystic liver disease.
Gevers TJ; Drenth JP
Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):101-8. PubMed ID: 23296249
[TBL] [Abstract][Full Text] [Related]
6. Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease.
Yang J; Ryu H; Han M; Kim H; Hwang YH; Chung JW; Yi NJ; Lee KW; Suh KS; Ahn C
Hepatol Res; 2016 Feb; 46(2):183-91. PubMed ID: 26190457
[TBL] [Abstract][Full Text] [Related]
7. Center is an important indicator for choice of invasive therapy in polycystic liver disease.
D'Agnolo HM; Kievit W; van Munster KN; van der Laan JJ; Nevens F; Drenth JP
Transpl Int; 2017 Jan; 30(1):76-82. PubMed ID: 27732751
[TBL] [Abstract][Full Text] [Related]
8. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
[No Abstract] [Full Text] [Related]
9. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
10. Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil.
Wang MQ; Duan F; Liu FY; Wang ZJ; Song P
Abdom Imaging; 2013 Jun; 38(3):465-73. PubMed ID: 22743841
[TBL] [Abstract][Full Text] [Related]
11. Treatment of polycystic liver disease. Update on the management.
Aussilhou B; Dokmak S; Dondero F; Joly D; Durand F; Soubrane O; Belghiti J
J Visc Surg; 2018 Dec; 155(6):471-481. PubMed ID: 30145049
[TBL] [Abstract][Full Text] [Related]
12. Polycystic Liver Disease: Advances in Understanding and Treatment.
Masyuk TV; Masyuk AI; LaRusso NF
Annu Rev Pathol; 2022 Jan; 17():251-269. PubMed ID: 34724412
[TBL] [Abstract][Full Text] [Related]
13. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.
Schnelldorfer T; Torres VE; Zakaria S; Rosen CB; Nagorney DM
Ann Surg; 2009 Jul; 250(1):112-8. PubMed ID: 19561475
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.
Neijenhuis MK; Gevers TJ; Hogan MC; Kamath PS; Wijnands TF; van den Ouweland RC; Edwards ME; Sloan JA; Kievit W; Drenth JP
Hepatology; 2016 Jul; 64(1):151-60. PubMed ID: 26970415
[TBL] [Abstract][Full Text] [Related]
15. Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.
Kim H; Park HC; Ryu H; Kim K; Kim HS; Oh KH; Yu SJ; Chung JW; Cho JY; Kim SH; Cheong HI; Lee K; Park JH; Pei Y; Hwang YH; Ahn C
PLoS One; 2015; 10(12):e0144526. PubMed ID: 26641645
[TBL] [Abstract][Full Text] [Related]
16. Current treatment status of polycystic liver disease in Japan.
Ogawa K; Fukunaga K; Takeuchi T; Kawagishi N; Ubara Y; Kudo M; Ohkohchi N
Hepatol Res; 2014 Oct; 44(11):1110-8. PubMed ID: 24308726
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic cyst fenestration in the treatment of polycystic liver disease.
Pantè S; Di Dio V; Putorti A; Salvo A; Barbera N; Catalfamo G; Leonello G; Mastrojeni C
Ann Ital Chir; 2014; 85(3):298-303. PubMed ID: 25073657
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up.
Zhang JL; Yuan K; Wang MQ; Yan JY; Xin HN; Wang Y; Liu FY; Bai YH; Wang ZJ; Duan F; Fu JX
Chin Med J (Engl); 2017 Aug; 130(16):1938-1944. PubMed ID: 28776546
[TBL] [Abstract][Full Text] [Related]
19. Treatment of highly symptomatic polycystic liver disease. Preliminary experience with a combined hepatic resection-fenestration procedure.
Newman KD; Torres VE; Rakela J; Nagorney DM
Ann Surg; 1990 Jul; 212(1):30-7. PubMed ID: 2363601
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
